🔎 Trials Near Me

Home › Stroke › NCT05338697

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

RecruitingObservational study

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Age 18 years or older
2. Unilateral symptomatic stroke due to ischemia. (Note: Bilateral acute stroke is permitted if the stroke that is contralateral to the index stroke is asymptomatic).
3. Motor deficits in the acutely affected UE, defined as a Shoulder Abduction and Finger Extension (SAFE) score ≤ 8 out of 10 points20,61 (i.e., excluding full or nearly full motor strength in both shoulder abduction and finger extension) within 48 to 96 hours of stroke onset (or time last known well).

   a. Please note that, if significant imbalance is observed in SAFE score or MEP+ rates, the enrollment threshold for SAFE score may be updated with a formal study memo.
4. Provision of signed and dated informed consent form within 24 to 96 hours of stroke onset, (or time last known well). Note: Participant is considered "enrolled" upon starting TMS (at least one stimulation is delivered) or starting study-specific MRI pulse sequence (at least one MRI beep occurs)
5. Stated willingness to comply with all study procedures and availability for the duration of the study, including Day 90 visit which must occur in-person.
6. Fluent in study approved languages (i.e., English or Spanish)

Exclusion Criteria:

1. UE injury or conditions on paretic side that limited use prior to the stroke
2. Legally blind
3. Dense sensory loss on paretic side indicated by a score of 2 on NIHSS sensory item
4. Unable to abduct the shoulder or extend the fingers of the non-paretic UE on verbal command
5. Isolated cerebellar stroke
6. Symptomatic stroke in any location within 30 days prior to index stroke.
7. Co-enrollment in a trial of an intervention targeting the incident stroke (acute treatment or rehabilitation/recovery intervention) after baseline assessments for VERIFY are initiated
8. Known or expected inability to maintain follow-up with study procedures through 90 days
9. Cognitive or communication impairment precluding informed consent by the participant.
10. Major medical, neurological, or psychiatric condition that would substantially affect functional status
11. Non-cerebrovascular diagnosis associated with unlikely survival at 90 days
12. Pregnancy
13. Contraindication to noncontrast MRI (certain metallic implants, metallic foreign bodies or severe claustrophobia)
14. Contraindication to TMS

    1. Implanted electronic cardiac devices (e.g., Automatic Implantable Cardioverter-Defibrillator \[AICD\] or pacemaker)
    2. Any electronic devices in the body at or above the level of the seventh cervical vertebra (such as cochlear implant, cortical stimulator, deep brain stimulator, vagus nerve stimulator, cervical spine epidural stimulator, or ventriculoperitoneal shunt)
    3. Ferromagnetic intracranial metallic implant
    4. Skull defect related to current stroke
    5. Seizure after onset of current stroke
    6. Seizure within the last 12 months while taking anti-epileptic medications
    7. Previous serious adverse reaction to TMS
15. Anticipated inability to perform study procedures within 168 hours of symptom onset

    1. Unable to perform behavioral assessments within 48-120 hours of symptom onset (or time last known well).
    2. Unable to receive TMS within 72-168 hours or get MRI within 48-168 hours of symptom onset (or time last known well).

About the study

VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.

What is being tested

Sponsor: Yale University · Participants: 657 · Started: Jun 18, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05338697

Locations in the U.S.

AlabamaBirmingham VA Medical Center, Birmingham
University of Alabama, Birmingham
ArizonaBanner University Medical Center, Tucson
CaliforniaKeck Medical Center of USC, Los Angeles
Kaiser Permanente Redwood City Medical Center, Redwood City
San Francisco General Hospital, San Francisco
UCSF Medical Center, San Francisco
ConnecticutYale New Haven Hospital, New Haven
District of ColumbiaMedStar Washington Hospital Center, Washington D.C.
GeorgiaEmory University Hospital, Atlanta
IllinoisMemorial Hospital of Carbondale, Carbondale
Advocate Lutheran General Hospital, Park Ridge
IndianaIU Health Methodist Hospital, Indianapolis
IowaUniversity of Iowa Hospitals & Clinics, Iowa City
MassachusettsMassachusetts General Hospital, Boston
Lahey Hospital & Medical Center, Burlington
Baystate Medical Center, Springfield
MichiganUniversity of Michigan, Ann Arbor
Corewell Heath Butterworth Hospital, Grand Rapids
MinnesotaMayo Clinic Saint Marys Campus, Rochester
New YorkThe Mount Sinai Hospital, New York
Strong Memorial Hospital, Rochester
Montefiore Medical Center, The Bronx
Westchester Medical Center, Valhalla
North CarolinaDuke University Hospital, Durham
OhioUniversity of Cincinnati Medical Center, Cincinnati
OSU Wexner Medical Center, Columbus
PennsylvaniaPenn State Hershey Medical Center, Hershey
Pennsylvania Hospital, Philadelphia
UPMC Presbyterian Hospital, Pittsburgh
South CarolinaMedical University of South Carolina (MUSC), Charleston
Prisma Health Richland Hospital, Columbia
TexasUT Southwestern Medical Center, Dallas
Memorial Hermann Texas Medical Center, Houston
UtahUniversity of Utah Healthcare, Salt Lake City
VirginiaUVA Medical Center, Charlottesville
WashingtonHarborview Medical Center, Seattle
WisconsinUniversity of Wisconsin University Hospital, Madison
Aurora St. Luke's Medical Center, Milwaukee
Froedtert & Medical College of Wisconsin, Milwaukee

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.